Public Citizen: State drug fraud cases on the rise

by Matthew Perrone

(AP)—A consumer advocacy group is reporting that pharmaceutical companies have paid more than $30 billion to state and federal governments to settle allegations of fraud over the last 20 years.

The report shows a recent uptick in settlements by state attorneys with drugmakers like and Eli Lilly & Co. The analysis by Public Citizen finds that state governments collected $3.7 billion from drugmakers in the past three years. That was roughly six times more money than in the previous 18 years combined. Overcharging state Medicaid plans was the most common violation.

Governments are spending more on prescription drugs as programs like Medicare and Medicaid swell with aging baby boomers. That increased spending has attracted scrutiny from government investigators looking for potential fraud.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

10 drugmakers team up to improve testing process

Sep 19, 2012

(AP)—Pharmaceutical industry heavyweights are teaming up to address a challenge that's long vexed drugmakers: how to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Savings help the medicine go down

Jun 25, 2008

[B]Prescription drug coverage for low income seniors reduces Medicaid[/B] A new study of state-subsidized pharmacy assistance programs showed that providing prescription drug coverage for low-income seniors reduces Medicaid and ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments